BioCentury | Jan 4, 2021
Deals

Angelini adds registrational epilepsy program via $610M Arvelle takeout

...sell its 12% stake to Angelini and remains eligible for milestones. Other investors in Arvelle include NovaQuest Capital Management...
BioCentury | May 28, 2020
Finance

May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys

...the final $42.7 million tranche of Arvelle Therapeutics GmbH’s $133.3 million series A. Investors included NovaQuest Capital Management...
BioCentury | Nov 11, 2019
Emerging Company Profile

Mycovia tackling chronic infections with antifungal pipeline

...been left behind,” said CEO Patrick Jordan, who is also a partner at Mycovia investor NovaQuest Capital Management...
...Durham, N.C. Technology: Oral antifungals Disease focus: Infectious Clinical status: Phase III Founded: 2018 by NovaQuest Capital Management...
...Richter plc, Jiangsu Hengrui Medicine Co. Ltd. Number of employees: 20 Funds raised: Undisclosed Investors: NovaQuest Capital Management...
BioCentury | Nov 16, 2018
Financial News

Roivant, now valued at $7B, raises $200M in equity financing

...on Nov. 13, which Roivant says values the company at about $7 billion. New investors NovaQuest Capital Management...
BioCentury | Nov 13, 2018
Financial News

Roivant, now valued at $7B, raises $200M in equity financing

...fourth equity financing, which Roivant says values the company at about $7 billion. New investors NovaQuest Capital Management...
BioCentury | Aug 31, 2018
Company News

Dermavant, NovaQuest in milestone deal for tapinarof

...Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) received the $100 million investment from NovaQuest Capital Management...
...Basel, Switzerland NovaQuest Capital Management LLC, Raleigh, N.C. Business: Dermatology Alicia Parker GSK2894512, WBI-1001, tapinarof Roivant Sciences GmbH Aryl hydrocarbon receptor (AHR) NovaQuest Capital Management...
BioCentury | Aug 28, 2018
Company News

Roivant units Urovant, Dermavant in deals as NEA’s Torti joins ‘vant’ team

...forming subunit of the large conductance potassium channel. Dermavant received the $100 million investment from NovaQuest Capital Management...
BioCentury | Sep 1, 2014
Company News

Pharmaxis pulmonary news

...Pharmaxis filed suit in the Supreme Court of the State of New York alleging that NovaQuest Capital Management...
BioCentury | Jul 14, 2014
Financial News

Pharmaxis financial update

...Autoimmune Date announced: 2014-07-08 Note: Pharmaxis disclosed that on July 4 it received notice from NovaQuest Capital Management...
BioCentury | Nov 4, 2013
Financial News

NovaQuest Capital Management LLC financial update

...NovaQuest Capital Management spun out of CRO Quintiles Transnational Corp. (NYSE:Q, Research Triangle Park, N.C.) in 2010. NovaQuest Capital Management...
Items per page:
1 - 10 of 12
BioCentury | Jan 4, 2021
Deals

Angelini adds registrational epilepsy program via $610M Arvelle takeout

...sell its 12% stake to Angelini and remains eligible for milestones. Other investors in Arvelle include NovaQuest Capital Management...
BioCentury | May 28, 2020
Finance

May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys

...the final $42.7 million tranche of Arvelle Therapeutics GmbH’s $133.3 million series A. Investors included NovaQuest Capital Management...
BioCentury | Nov 11, 2019
Emerging Company Profile

Mycovia tackling chronic infections with antifungal pipeline

...been left behind,” said CEO Patrick Jordan, who is also a partner at Mycovia investor NovaQuest Capital Management...
...Durham, N.C. Technology: Oral antifungals Disease focus: Infectious Clinical status: Phase III Founded: 2018 by NovaQuest Capital Management...
...Richter plc, Jiangsu Hengrui Medicine Co. Ltd. Number of employees: 20 Funds raised: Undisclosed Investors: NovaQuest Capital Management...
BioCentury | Nov 16, 2018
Financial News

Roivant, now valued at $7B, raises $200M in equity financing

...on Nov. 13, which Roivant says values the company at about $7 billion. New investors NovaQuest Capital Management...
BioCentury | Nov 13, 2018
Financial News

Roivant, now valued at $7B, raises $200M in equity financing

...fourth equity financing, which Roivant says values the company at about $7 billion. New investors NovaQuest Capital Management...
BioCentury | Aug 31, 2018
Company News

Dermavant, NovaQuest in milestone deal for tapinarof

...Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) received the $100 million investment from NovaQuest Capital Management...
...Basel, Switzerland NovaQuest Capital Management LLC, Raleigh, N.C. Business: Dermatology Alicia Parker GSK2894512, WBI-1001, tapinarof Roivant Sciences GmbH Aryl hydrocarbon receptor (AHR) NovaQuest Capital Management...
BioCentury | Aug 28, 2018
Company News

Roivant units Urovant, Dermavant in deals as NEA’s Torti joins ‘vant’ team

...forming subunit of the large conductance potassium channel. Dermavant received the $100 million investment from NovaQuest Capital Management...
BioCentury | Sep 1, 2014
Company News

Pharmaxis pulmonary news

...Pharmaxis filed suit in the Supreme Court of the State of New York alleging that NovaQuest Capital Management...
BioCentury | Jul 14, 2014
Financial News

Pharmaxis financial update

...Autoimmune Date announced: 2014-07-08 Note: Pharmaxis disclosed that on July 4 it received notice from NovaQuest Capital Management...
BioCentury | Nov 4, 2013
Financial News

NovaQuest Capital Management LLC financial update

...NovaQuest Capital Management spun out of CRO Quintiles Transnational Corp. (NYSE:Q, Research Triangle Park, N.C.) in 2010. NovaQuest Capital Management...
Items per page:
1 - 10 of 12